<DOC>
	<DOCNO>NCT01202084</DOCNO>
	<brief_summary>The primary objective compare impact study formulation pulmonary function persistent asthma carrier .</brief_summary>
	<brief_title>A Study Comparative Formoterol/Fluticasone Foraseq® Fluticasone Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Sign ICF Age ≥ 12 year Persistent asthma diagnosis , per GINA classification ( www.ginasthma.com ) ,18 symptom least 6 month clinically stable least 1 month , ACQ745 test ( see Appendix C ) ≤ 3.0 Current use inhale corticosteroid ( beclomethasone dipropionate dose 1000 µg ) , associate longterm β2adrenergic agent breakthrough medication ( salbutamol equivalent ) Initial FEV1 least 40 % predict normal value Serum cortisol assessment within normal value . Use oral parenteral corticosteroid within 3 month prior study begin Requirement admission due asthma within 3 month prior study begin Presence active smoking , define use cigarette , pipe , cigar form smoking amount within last 3 month Presence severe comorbidities , cardiovascular , renal , liver , neurological , neoplastic , hematological , infectious , dermatological , neurological , psychiatric chronic respiratory disease asthma Recent ( &lt; 6 month ) predict participation study clinical study involve drug nature study form intervention treat asthma Intolerance allergy component drug assess study Pregnancy lactation Chronic use βblocker medication , per routine oral intravenous route , also ophthalmic solution</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>